Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has provided an announcement.
ResMed Inc. has announced a proposed sale of securities under Rule 144, with Director Peter C. Farrell planning to sell 2,000 common shares. The sale, facilitated by Merrill Lynch, is part of a series of transactions by Farrell, who has previously sold shares in December 2024 and January 2025, indicating ongoing divestment activities. The aggregate market value of the shares to be sold is $500,000, reflecting a strategic financial decision that may impact stakeholder perceptions and the company’s market dynamics.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, focusing on the development and manufacturing of equipment related to sleep disorders, respiratory care, and connected health solutions. The company is known for its innovative products that cater to patients with sleep apnea and other chronic respiratory conditions, positioning itself as a leader in the medical device market.
YTD Price Performance: 2.94%
Average Trading Volume: 1,024,863
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$54.39B
See more data about RMD stock on TipRanks’ Stock Analysis page.